Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 1 , ISSUE 2 ( July-December, 2011 ) > List of Articles


Update on Management of Viral Hepatitis B

Desmond Wai

Citation Information : Wai D. Update on Management of Viral Hepatitis B. Euroasian J Hepatogastroenterol 2011; 1 (2):49-52.

DOI: 10.5005/jp-journals-10018-1013

License: CC BY-NC 4.0

Published Online: 01-01-2011

Copyright Statement:  Copyright © 2011; The Author(s).


Management of hepatitis B has gone a long way since the introduction of lamivudine and interferon. Today, we have several much more potent oral antivirals for hepatitis B, which are associated with much less resistance. Pegylated interferon has the path for immune modulation and newer immune modulators are in the pipeline. Options of combination therapy are being evaluated, while treatment is being individualized. Although the best treatment for hepatitis B is yet to be identified, the prospects are brighter than ever before.

PDF Share
  1. Mahtab MA, Rahman S, Karim MF, Khan M, Foster G, Solaiman S, et al. Epidemiology of hepatitis B virus in Bangladeshi general population. Hepatobiliary Pancreat Dis Int Dec 2008;7(6):595-600
  2. Treatment of hepatitis B. J Gastroenterol 2002;37(10):771-78
  3. Chronic hepatitis B: Update 2009. Hepatology Sep 2009;50(3):661-62
  4. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 21 Jul 2006;12(27):4325-30
  5. Cirrhosis Asian lamivudine multicentre study group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 7 Oct 2004;351(15):1521-31
  6. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg June 2011;146(6):675-81. Desmond Wai 52 JAYPEE 7. Chen CJ, Yang HI, Iloeje UH. Reveal-HBV study group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology May 2009;49(5S):S72-84
  7. Endpoints of therapy in chronic hepatitis B. Hepatology May 2009;49(5S):S96-S102
  8. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut Oct 2002;51(4):597-99
  9. Hepatitis B virus drug resistance working group. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology July 2007;46(1):254-65
  10. Chronic hepatitis B: Peginterferon or nucleos(t)ide analogues? Liver Int Jan 2011;31(S1):78-84
  11. Systematic review: Treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 15 Sep 2005;22(6):519-28
  12. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology Dec 2002;36(6):1425-30
  13. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses. Gastroenterology Oct 2010;139(4):1218-29
  14. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferonalpha 2b and lamivudine with lamivudine alone. Ann Intern Med 15 Feb 2005;142(4):240-50
  15. Public misperceptions about transmission of hepatitis B virus in Singapore. Ann Acad Med Singapore Oct 2007;36(10):797-800
  16. Misperceptions among patients with chronic hepatitis B in Singapore. World J Gastroenterol 28 Aug 2005;11(32): 5002-05
  17. Utility of the health belief model in predicting compliance of screening in patients with chronic hepatitis B. Aliment Pharmacol Ther 15 May 2005;21(10):1255-62
  18. Age in guiding strategy in hepatitis A vaccination. Am J Med Aug 2007;120(8):e17-18.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.